Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy ...

Novavax Inc. closed 61.37% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax Inc. closed 60.92% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid concerns about rare side effects.

NVAX opened at $7.92 on Friday. The stock’s fifty day simple moving average is $8.46 and its 200 day simple moving average is $9.71. Novavax has a 1-year low of $3.81 and a 1-year high of $23.86.

Novavax, Inc. (NYSE:NVAX) is actively advancing its late-stage pipeline, which includes the development of a COVID-19 Influenza Combination (CIC) vaccine and a standalone influenza vaccine.

Novavax, Inc. (NASDAQ:NVAX) shares have surged around 50% over the past one-year. Overall, NVAX ranks 1st on our list of unstoppable stocks that could double your money.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.